Protocol
11-061
Full Title
Pilot Study of Bortezomib/Dexamethasone (BD), Followed By Autologous Stem Cell Transplantation and Maintenance Bortezomib/Dexamethasone For the Initial Treatment of Monoclonal Immunoglobulin Deposition Disease (MIDD) Associated With Multiple Myeloma and AL Amyloidosis
Purpose
Monoclonal immunoglobulin deposition disease (MIDD — also known as Light Chain Deposition Disease, or LCDD) and amyloidosis are two rare conditions associated with abnormal plasma cells. The purpose of this study is to evaluate a treatment regimen that consists of the drugs bortezomib and dexamethasone, followed by a transplant of a patient’s own stem cells (autologous stem cell transplantation), and then another round of bortezomib and dexamethasone as maintenance therapy in patients with MIDD or amyloidosis.
Investigator
Co-Investigators
Eligibility
To be eligible for this study, patients must meet several criteria, including but not limited to the following:
- Patients must have MIDD/LCDD or amyloidosis.
- Patients may not have already been treated for the disease, with the exception of one cycle of dexamethasone.
- Patients may not have had prior treatment with bortezomib.
- At least 3 weeks must have passed since completion of any prior radiation therapy.
- Patients must be able to be ambulatory for more than half of their normal waking hours.
- Patients must be age 18 or older.
For more information about this study and to inquire about eligibility, please contact Dr. Hani Hassoun at 212-639-3228.
Disease(s)
Hematology: Hematologic Disorders
Hematology: Hematologic Malignancies
Hematology: Multiple Myeloma
Locations
ClinicalTrials.gov
Related Diseases
